Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells

被引：27
|
作者：
Del Re, Marzia [1 ]
Arrigoni, Elena [1 ]
Restante, Giuliana [1 ]
Passaro, Antonio [2 ]
Rofi, Eleonora [1 ]
Crucitta, Stefania [1 ]
De Marinis, Filippo [2 ]
Di Paolo, Antonello [1 ]
Danesi, Romano [1 ]
机构：
[1] Univ Pisa, Dept Clin & Expt Med, Clin Pharmacol & Pharmacogenet Unit, Pisa, Italy
[2] European Inst Oncol, Div Thorac Oncol, Milan, Italy
来源：
STEM CELLS | 2018年 / 36卷 / 05期
关键词：
Cancer stem cells; Treatment resistance; Tyrosine kinase inhibitors; Biomarkers; Tumor heterogeneity; GROWTH-FACTOR-RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; ACQUIRED-RESISTANCE; EGFR-TKI; DRUG-RESISTANCE; DNA METHYLATION; GENETIC-HETEROGENEITY; TUMOR HETEROGENEITY; T790M MUTATION; PROTEIN-KINASE;
D O I：
10.1002/stem.2787
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
Among the potential mechanisms involved in resistance to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer, the manifestation of stem-like properties in cancer cells seems to have a crucial role. Alterations involved in the development of TKI resistance may be acquired in a very early phase of tumorigenesis, supporting the hypothesis that these aberrations may be present in cancer stem cells (CSCs). In this regard, the characterization of tumor subclones in the initial phase and the identification of the CSCs may be helpful in planning a specific treatment to target selected biomarkers, suppress tumor growth, and prevent drug resistance. The aim of this review is to elucidate the role of CSCs in the development of resistance to TKIs and its implication for the management of patients.
引用
收藏
页码：633 / 640
页数：8
相关论文
共 50 条
  • [1] Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
    Rath, Barbara
    Plangger, Adelina
    Hamilton, Gerhard
    [J]. CANCER DRUG RESISTANCE, 2020, 3 (02) : 171 - 178
  • [2] Drug Resistance to EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Soh, Junichi
    Miyoshi, Shinichiro
    Toyooka, Shinichi
    [J]. ACTA MEDICA OKAYAMA, 2014, 68 (04) : 191 - 200
  • [3] The role of EGFR tyrosine kinase inhibitors in the treatment of non-small cell lung cancer
    Kowalczyk, Anna
    Szutowicz-Zielinska, Ewa
    Dziadziuszko, Rafal
    Jassem, Jacek
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2005, 1 (04): : 217 - 224
  • [4] Tyrosine kinase inhibitors in the management of non-small cell lung cancer
    Perol, M.
    Arpin, D.
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : S188 - S197
  • [5] Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
    Krawczyk, Pawel
    Mlak, Radoslaw
    Powrozek, Tomasz
    Nicos, Marcin
    Kowalski, Dariusz M.
    Wojas-Krawczyk, Kamila
    Milanowski, Janusz
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (05): : 401 - 406
  • [6] Defining the Role of Tyrosine Kinase Inhibitors in Early Stage Non-Small Cell Lung Cancer
    Lampaki, Sofia
    Lazaridis, George
    Zarogoulidis, Konstantinos
    Kioumis, Ioannis
    Papaiwannou, Antonis
    Tsirgogianni, Katerina
    Karavergou, Anastasia
    Tsiouda, Theodora
    Karavasilis, Vasilis
    Yarmus, Lonny
    Darwiche, Kaid
    Freitag, Lutz
    Sakkas, Antonios
    Kantzeli, Angeliki
    Baka, Sofia
    Hohenforst-Schmidt, Wolfgang
    Zarogoulidis, Paul
    [J]. JOURNAL OF CANCER, 2015, 6 (06): : 568 - 574
  • [7] Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib
    Dediu, Mircea
    Median, Dragos
    Alexandru, Aurelia
    Vremes, Georgeta
    Gal, Cristian
    [J]. JOURNAL OF BUON, 2007, 12 : S137 - S149
  • [8] Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
    Vavala, Tiziana
    Mariniello, Annapaola
    Novello, Silvia
    [J]. TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S48 - S54
  • [9] Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature
    van der Wekken, A. J.
    Saber, A.
    Hiltermann, T. J. N.
    Kok, K.
    van den Berg, A.
    Groen, H. J. M.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 : 107 - 116
  • [10] Identification of novel mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    de Bruin, Elza C.
    Cowell, Catherine F.
    Howell, Michael
    Varmus, Harold E.
    Politi, Katerina
    Downward, Julian
    [J]. CANCER RESEARCH, 2011, 71
12345